Golf, thank you for your post I totally agree.

Jonzo thank you for your post, we obviously disagree on a number of points but that's what makes it a market. Some comments on your post 1) RSUs are in fact cash payments, they are just deferred cash in terms of when they vest. They are probably the best type of "other" compensation for poor managers because there is no strike price and they generally don't expire.  Unless there is a complete corporate failure they are worth something, even if undeserved.  2) Under "Management is incompetent" you neglected to address what in my view are the three biggest factors in this regard. The first being the complete disaster that is RVX financial management.  The second being when has management been on time, on budget or in general right about anything when it comes to the business of the company?  The third being that after 20 years and some incredible scientific achievements this company is not covered by a single credible analyst, that to me screams "incompetent management".

Tada I sincerely doubt that what is said on this forum is the root of new investors staying away from RVX or perhaps more importantly current investors buying more shares.  Anything negative said here would be overcome quickly if management started to perform in terms of getting the financial house in order, getting business done roughly within the time frames that management themselves lays out and basically started to deliver with regularity on what they promise. As Golf said narrow the chasm between what Don says and what actually happens. 

In very general terms I think many investors are looking for two things in biotech; firstly they are looking for technology that if it pans out, the risk, that it promises to pay off handsomely, the reward.  I think RVX science still holds that potential in spades. Secondly they are looking to see if they think management is capable of delivering on the technology's promise. To me RVX management has and continues to fail miserably at demonstrating this. I still know people who won't invest now but say they would pay $5/share for the science if they could see a clear financial path forward. A plan that demonstrated how the company is going to get where it wants to go and where an investment made at a given point in time can be reasonably expected to be in terms of future dilution.  

Don said on Feb 4 that he expected enrolment to begin in March on a CoVid clinical trial but that it might "bleed into April". Hopefully he will be close to accurate and this trial can be the first step to RVX regaining some of the market's trust that management has unfortunately squandered.